Zenas BioPharma, Inc.
ZBIO
$25.87
$1.204.86%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -161.21% | -140.62% | -47.24% | -223.26% | -255.16% |
| Total Depreciation and Amortization | -69.29% | -59.12% | -41.04% | -16.13% | 7.63% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1,302.90% | 1,640.14% | 264.63% | 193.81% | -0.91% |
| Change in Net Operating Assets | -100.54% | -96.26% | -93.78% | -33.60% | 44.94% |
| Cash from Operations | -52.94% | -44.00% | -64.19% | -341.49% | -483.94% |
| Capital Expenditure | 98.43% | 86.26% | -24.32% | -24.32% | -225.64% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -14.85% | -727.94% | -506.00% | -- | -- |
| Cash from Investing | -14.72% | -724.45% | -504.67% | -309,440.54% | -299,397.44% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 32.52% | -36.51% | -96.13% | 112,199.07% | 233,849.51% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -100.00% | -100.00% | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 1,188.82% | 1,084.13% | 3,711.12% | -245.43% | -765.55% |
| Cash from Financing | 56.81% | -47.87% | -81.44% | 20.53% | 2,027.17% |
| Foreign Exchange rate Adjustments | -840.58% | -260.51% | -71.83% | -1,226.67% | -42.02% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 90.61% | -179.57% | -185.00% | -185.65% | 4,042.42% |